scholarly journals Using Inside-Out Open Innovation to Recover Abandoned Pharmaceutical Compounds

2015 ◽  
Vol 3 (2) ◽  
pp. 21-32 ◽  
Author(s):  
Henry Chesbrough ◽  
Eric L. Chen

Pharmaceutical drug development costs have risen rapidly over the past twenty years.  However, the number of new molecular entities being approved has not increased.  As pharmaceutical companies scale back their R&D in light of this deteriorating productivity, significant unmet medical needs remain unaddressed.  Much of these rising costs can be traced to work on compounds that are abandoned before getting to market.  There is a growing need to recover these abandoned compounds. The inside-out branch of open innovation provides a way to increase the performance of pharmaceutical firms, both in addressing unmet societal needs, and potentially in identifying new revenue sources and business models for a more distributed model of commercializing new drugs.  This aspect of open innovation is not much discussed in the literature to date. The medical research community, in conjunction with a number of industry and nonprofit organizations, has started several projects to recover more abandoned compounds.  These new initiatives are still at an early stage, and have not received much critical evaluation to date.  Examining four of these initiatives, we find that they do extend the cognitive frames in the research phase, while doing less to extend those frames in the commercialization phase.

Author(s):  
Kisoon Shin ◽  
Daeho Lee ◽  
Kwangsoo Shin ◽  
Eungdo Kim

The pharmaceutical industry, where research and development (R&D) efficiency is central to company survival, has recently faced significant challenges. To increase efficiency, companies must implement strategies such as open innovation (OI), wherein they sell their intellectual property, maximize their use of external resources, adjust their structures, and implement new business models. In this study, we divided 701 U.S. pharmaceutical companies according to their OI strategies to measure and compare their R&D efficiencies between 2001 and 2016. We analyzed the deal data of companies by first dividing them into four groups (inside-out, outside-in, coupled, and closed) to calculate R&D efficiency using stochastic and meta-frontier analyses. In the first group analysis, the coupled group shows high technical efficiency, but in an overall comparison, the inside-out group achieves the highest efficiency values. These values increased between 2005 and 2010, when the R&D crisis in the industry was great at its highest. We thus identified the characteristics of each group based on our results, and presented extensive analyses using a time-series comparison and enterprise-level analysis. We claim that pharmaceutical companies can still cope with the current R&D crisis by implementing different OI strategies.


Author(s):  
Yunming Shao ◽  
Lei Shi

This paper is a case study of FORGE, the first UK-China cross border accelerator program, conducted in the context of TusPark Newcastle, an overseas innovation center by TUS Holdings in the United Kingdom. It engages with current research that examines the role of trust, particularly in the area of cross-border trade. We suggest that this is especially pertinent for early stage technology companies, since in many cases, their products, business models and even founder reputations, are more unformed. We also look at the topic of cross-border incubation, particularly with China as the target market, and provide new insights for understanding the channels and barriers for international commercialization in China for early stage tech startups. Finally, we provide some suggestions for policy-makers on both sides to better coordinate efforts to increase innovation relationships like FORGE.


2020 ◽  
Vol 12 (14) ◽  
pp. 5535
Author(s):  
Arisa Djurian ◽  
Tomohiro Makino ◽  
Yeongjoo Lim ◽  
Shintaro Sengoku ◽  
Kota Kodama

A key concept in the pharmaceutical industry is open innovation, in which pharmaceutical companies contribute to human health and adapt to a changing business environment by acquiring external knowledge. As successful drug discoveries and developments have become challenging, pharmaceutical companies must proactively pursue the open innovation of new drugs through various inter-firm partnerships to be more sustainable. This study aims to interpret the trend of inter-firm partnerships in the development of cancer drugs and to evaluate their effectiveness by examining inter-firm transactions related to cancer drugs approved by the US Food and Drug Administration (FDA). It is a novel approach to exercise this on each product instead of at the company level. The findings revealed that the number of inter-firm transactions in the oncology field has increased over the past 20 years. Furthermore, the annual number of transactions related to biologics has surpassed that of small molecules since 2015 and has been primarily driven by three PD-(L)1 inhibitors: Keytruda, Opdivo, and Tecentriq. Moreover, the average number of inter-firm transactions related to biologics is significantly higher than that of small molecules in total, in alliances, and in financing, suggesting that inter-firm transactions for biologic cancer drugs actively occur through various means. Additionally, a positive and significant correlation exists between the number of transactions and the average number of approved indications for biologics, but not for small molecules. These results suggest that the observed trend of active inter-firm transactions is key in increasing the probability of success in cancer drug research and development. This could provide a potential breakthrough in this industry for the successful development of innovative drug candidates to address unmet medical needs. Further study is necessary to confirm the applicability of this paradigm in broader drug discoveries and development.


Author(s):  
Nuša FAIN ◽  
Beverly WAGNER

Open innovation has been described as a means of assisting firms utilising ideas and knowledge from inside and outside the firm.  It has been defined as “a distributed innovation process based on purposively managed knowledge flows across organisational boundaries, using pecuniary and non-pecuniary mechanisms in line with the organisations business model” (Chesbrough et al, 2014, p vi). Open innovation strategies may lead to better financial performance by reducing costs related to innovation, increasing commercialisation and financial gain. Understanding open innovation in some way explains how sharing knowledge with internal and external stakeholders can promote innovation.  Understanding processes can reinforce the importance of engaging with customers early in concept development and design stages of new products and services. Also openness can promote co-creation between firms, customers, suppliers, academia and government. The essence of such cooperation by internal and external stakeholders creates relationships to explore common interests and goals. From an open innovation perspective, value creation and capture is accomplished by (i) outside-in open innovation, i.e. ideas drawn into the organisation from the external environment. This involves opening up organisation’s innovation processes to external inputs and contributions, (ii) Inside-out open innovation utilises unused or underused ideas and assets gathered from outside the organisation and (iii) Coupled open innovation links outside-in and inside-out open innovation processes combining knowledge inflows and outflows to collaboratively develop and commercialise an innovation. Traditionally, knowledge is considered as being held by the firm as core competences and it is assumed that this is a source of sustainable competitive advantage. Accordingly knowledge used in, and resulting from, innovation and the knowledge resulting from the innovation remains within boundaries of the firm. Open innovation opposes this view as it integrates diverse knowledge from the wider environment into the business ecosystem and creates new knowledge for multiple stakeholders. Due to the inter-disciplinary nature of open innovation it can be discussed and theorised from many viewpoints, such as strategy, value chain, business models, core competencies, knowledge creation and more recently in design management. Levels of analysis vary with considerable research frequently conducted at organisational level, while more is needed in areas such as inter-organisational value networks. To date, large organisation have been at the focus of open innovation research, primarily because they are able implement open innovation to some degree without strategic change. More recently, open innovation practices in SMEs have become important, as these small firms have insufficient resources to cover all innovation activities and must look beyond firm boundaries for growth opportunities. Thus, inter-organisational networks are important drivers of innovation in SMEs as they often struggle to make the best use of strong network ties.  Exploring open innovation in SMEs can provide insight into how best to utilise their networks.


2019 ◽  
pp. 28-50
Author(s):  
Henry Chesbrough

This chapter reviews the core ideas behind Open Innovation, discusses what it is and is not, and shows how it can deliver more value to organizations and to society. Outside-in Open Innovation strengthens the current business and current business model, while inside-out Open Innovation searches for alternative businesses and business models. The chapter explores the connection between technology development and the business model, and examines the use of Open Innovation in intellectual property and in services. However, Open Innovation is not a panacea. Its boundary conditions and limitations must also be acknowledged. As with Chapter 1, the processes of generation in innovation must also be supported by equal attention to innovation dissemination and innovation absorption within the firm, in order for organizations to create and capture value from Open Innovation. Finally, Open Innovation is moving beyond collaborations between two actors, to a broader ecosystem focus that connects many actors together.


2021 ◽  
Vol 7 (2) ◽  
pp. 149
Author(s):  
Magdalena Pichlak ◽  
Adam R. Szromek

The paper aims to analyze the environmental aspects of innovation activity undertaken by companies and, in particular, to assess sustainable business leaders’ propensity to generate eco-innovation. The research described in the paper was descriptive and, to some extent, diagnostic. It was based on a non-random sample and was conducted—using the Computer Assisted Telephone Interview (CATI) method—in 2019 among 54 of the most eco-innovative Polish companies. The results of the research indicate that they are more likely to generate radical rather than incremental changes. Moreover, the most eco-innovative companies are those developing technologies for biodiversity protection. The results further indicate that companies with more than 50 employees have a higher propensity to develop incremental and radical eco-innovation than smaller firms with relatively fewer resources. Finally, this study shows that adopting an open innovation strategy strengthens the propensity to generate eco-innovation, especially radical ones. Moreover, developing such changes is dominated by the adoption of strategic and operational forward supply chain collaboration, involving the absorption of knowledge and information streaming directly from the market. The results can provide a frame for developing new business models incorporating collaboration in eco-innovation activities, especially in the situation of a post-pandemic recovery of the economy.


1957 ◽  
Vol 33 (382) ◽  
pp. 396-401 ◽  
Author(s):  
J. H. Pannekoek

Author(s):  
Andrew W. Lo

AbstractFunding for early-stage biomedical innovation has become more difficult to secure at the same time that medical breakthroughs seem to be occurring at ever increasing rates. One explanation for this counterintuitive trend is that increasing scientific knowledge can actually lead to greater economic risk for investors in the life sciences. While the Human Genome Project, high-throughput screening, genetic biomarkers, immunotherapies, and gene therapies have made a tremendously positive impact on biomedical research and, consequently, patient lives, they have also increased the cost and complexity of the drug development process, causing many investors to shift their assets to more attractive investment opportunities. This suggests that new business models and financing strategies can be used to reduce the risk and increase the attractiveness of biomedical innovation so as to bring new and better therapies to patients faster.


2016 ◽  
Vol 42 (2-3) ◽  
pp. 429-450 ◽  
Author(s):  
Thomas J. Hwang ◽  
Aaron S. Kesselheim

Accelerating the development and approval of novel therapeutics has emerged as a key public health priority given the mortality, morbidity, and economic costs associated with infections caused by drug-resistant bacteria. However, there is limited empirical evidence to guide policymaking, such as the factors that may disadvantage antibiotics compared to other classes of drugs. In this Article, we empirically examine characteristics of the key clinical trials underpinning FDA's approval of antibiotics and other drugs over the past decade. Despite perceptions that antibiotic trials are larger and more difficult to conduct, we find that antibiotic trials are no larger than those conducted for drugs approved in other disease areas with high unmet medical needs, suggesting that policymakers may need to target other levers to meaningfully stimulate innovation. We discuss the risks and benefits of harnessing new and existing regulatory pathways to speed the approval of new drugs, particularly those intended to treat patients with serious and life-threatening infections, and we evaluate ways that proposals for new regulatory pathways could be improved to better prioritize and expedite the approval of therapies with the greatest potential for patient health benefits.


2012 ◽  
Author(s):  
Shkodran Zogaj ◽  
Philipp Kipp ◽  
Philipp Ebel ◽  
Ulrich Bretschneider ◽  
J. M. Leimeister
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document